BRCA1 and BRCA2 mutational profile, prevalence and testing criteria in hereditary breast and ovarian cancer (HBOC) probands from southern Brazil

Barbara Alemar, Cleandra Gregorio, Josef Herzog, Camila Matzenbacher Bittar, Cristina Brinckmann Oliveira Netto, Osvaldo Artigalas, Ida Vanessa D. Schwartz, Suzi Alves Camey, Jeffrey Weitzel, Patricia Ashton-Prolla - HCPA

Background: Germline mutations in BRCA1 and BRCA2 (BRCA) are the main cause of Hereditary Breast and Ovarian Cancer syndrome (HBOC). Methods: In this study we evaluated the mutational profile and prevalence of BRCA mutations among probands fulfilling the NCCN HBOC testing criteria. We characterized the clinical profile of these individuals and explored the performance of international testing criteria. Results: A pathogenic mutation was detected in 19.1% of 418 probands, including seven novel frameshift mutations. Variants of uncertain significance were found in 5.7% of individuals. We evaluated 50 testing criteria and mutation probability algorithms. There was a significant odds-ratio (OR) for mutation prediction (p ≤ 0.05) for 25 criteria; 14 of these had p ≤ 0.001. Using a cutoff point of four criteria, the sensitivity is 83.8%, and the specificity is 53.5% for being a carrier. Mutation prevalence for each criterion ranged from 22.1% to 55.6%, and criteria with the highest ORs were those related to triple-negative breast cancer or ovarian cancer. Conclusions: This is the largest study of comprehensive BRCA testing among Brazilians to date, and the first to analyze clinical criteria for genetic testing. Several criteria that are not included in the NCCN achieved a higher predictive value. Identification of the most informative criteria for each population will assist in the development of a rational approach to genetic testing, and will enable the prioritization of high-risk individuals as a first step towards offering testing in low-income countries. Palavras-chaves: BRCA1, BRCA2, HBOC